Latest news articles

Added 19 hours ago Drug news

Two analyses show benefits of Xarelto for patients with PAD and CAD.- Bayer + Janssen.

Two new analyses of data from the COMPASS trial show that Xarelto (rivaroxaban),from Bayer and Janssen ,significantly cut the amputation...

Added 19 hours ago Drug news

FDA approves remote programming via telemedicine of Nucleus Cochlear Implant System.- Cochlear Corporation.

The FDA has approved a remote feature for follow-up programming sessions for the Nucleus Cochlear Implant System, from Cochlear Corporation,...

Added 19 hours ago Drug news

Acorda Therapeutics increases blood cell monitoring in Phase III programme for tozadenant for Parkinson’s disease.

Acorda Therapeutics, Inc. announced that it has increased the frequency of blood cell count monitoring for participants to weekly in...

Added 1 day ago Drug news

FDA approves Sutent to treat high risk patients post surgery with renal cell carcinoma.- Pfizer

The FDA has approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk...

Added 2 days ago Drug news

Trelegy Ellipta triple therapy meets EU approval for COPD

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI’)...

Added 3 days ago Drug news

Trial analysis presented at the American Heart Association (AHA) shows Lixiana has greater reductions in ischaemic events compared to warfarin

Sub analysis of ENGAGE AF-TIMI 48 trial showed Lixiana has greater reductions in ischaemic events compared to warfarin.

Added 3 days ago Drug news

New digital medicine system granted first approval

FDA approves Abilify Mycite to treat schizophrenia, depression and bipolar I disorder

 

Added 3 days ago Drug news

Fasenra approved for treatment of severe asthma with eosinophilic phenotype

AstraZeneca and MedImmune, announced that the FDA has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Added 4 days ago Drug news

Innovative study presented at the American College of Rheumatology compare biosimilars with their reference medicines

Sandoz announces data from four clinical studies comparing proposed biosimilar adalimumab & biosimilar rituximab with their reference medicines, Humira and MabThera/Rituxan.

Added 4 days ago Drug news

New data shows 31% reduction in CardioVascular death with canakinumab

Novartis announced results from a new analysis of the Phase III CANTOS study presented by Dr. Paul Ridker at the American Heart Association (AHA) Scientific Sessions 2017

Search all news articles